Repaglinide vs insulin for newly diagnosed diabetes in patients with cystic fibrosis: A multicentre, open-label, randomised trial
The Lancet Diabetes & Endocrinology Jan 29, 2018
Ballmann M, et al. - Researchers compared the efficacy and safety of repaglinide vs insulin for newly diagnosed diabetes in patients with cystic fibrosis. For glycaemic control in patients with cystic-fibrosis-related diabetes, repaglinide was found to be as efficacious and safe as insulin.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
